Evidence map›Paper›PMID 35525105›Full record

ArticleClinical neurology and neurosurgery2022

Headache and cognitive disturbance correlate with ganglion cell layer thickness in patients who recovered from COVID-19.

Aslihan Taskiran-Sag, Erdal Eroglu, Kemal Ozulken, Sule Canlar, Baris Mustafa Poyraz, Manolya Berguzar Sekerlisoy, Tarkan Mumcuoglu

Open access · greenAbstract read
In one paragraph

Article in Clinical neurology and neurosurgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Aslihan Taskiran-SagDepartment of Neurology, Faculty of Medicine, TOBB ETU, 06510 Ankara, Turkey. Electronic address: aslihantaskiran@gmail.com.
Erdal ErogluDepartment of Neurology, Faculty of Medicine, TOBB ETU, 06510 Ankara, Turkey. Electronic address: drerdaleroglu@gmail.com.
Kemal OzulkenDepartment of Ophthalmology, Faculty of Medicine, TOBB ETU, 06510 Ankara, Turkey. Electronic address: kemalozulken@hotmail.com.
Sule CanlarDept. of Endocrinology and Metabolism, Faculty of Medicine, TOBB ETU, 06510 Ankara, Turkey. Electronic address: sulejan82@gmail.com.
Baris Mustafa PoyrazDepartment of Pulmonology, Faculty of Medicine, TOBB ETU, 06510 Ankara, Turkey. Electronic address: bpoyraz@tobbetuhastanesi.com.tr.
Manolya Berguzar SekerlisoyFaculty of Medicine, TOBB ETU, 06510 Ankara, Turkey. Electronic address: bm.sekerlisoy@gmail.com.
Tarkan MumcuogluDepartment of Ophthalmology, Faculty of Medicine, TOBB ETU, 06510 Ankara, Turkey. Electronic address: tarkanmumcuoglu@yahoo.com.
TOBB University of Economics and Technology · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRetinal abnormalities are being increasingly reported in COVID-19, in addition to the well-known symptoms of this disease accounting for the neurological involvement. In this study, we aimed to investigate whether ganglion cell layer thickness (GCLT) was different in recovered COVID-19 patients compared to controls in the subacute stage and to determine whether it correlated with COVID-19-related neurological symptoms or pneumonia.

methodsThis study involved 40 patients who had recovered from COVID-19 and 40 age- and sex-matched healthy controls. All the participants underwent ophthalmological examination, spectral domain optical coherence tomography and neurological examination. The clinical and biochemical properties of the patients were noted and their correlations with GCLT were sought.

resultsThe duration after COVID-19 infection was 113 ± 62 (mean ± SD) days. At this subacute stage, there was no significant difference between the GCLT measurements of the COVID-19 patients and the controls (14 ± 4.0 µm [median ± IQR] vs 16 ± 4.8 µm, respectively). When we analyzed the relationships with neurological symptoms in the patient group, we found that patients with cognitive symptoms had lower GCLT values compared to those without (13 ± 3 µm vs. 16 ± 4 µm, respectively; p = 0.002). Patients who suffered headache during the acute infection also had lower GCLT values compared to those without (14 ± 4 µm vs. 18 ± 5 µm, respectively; p = 0.015). The GCLT values did not differ significantly with respect to anosmia, ageusia, sleep disturbances, having had COVID-19 pneumonia, or smoking status. Age, duration after COVID-19, and blood levels of thyroid stimulating hormone, glucose, vitamin D and vitamin B12 were not in correlation with GCLT in our study.

conclusionOur findings highlight an association between GCLT values and neurological symptoms such as cognitive disturbance (brain fog) and headache in patients who had recovered after non-severe COVID-19 infection. Neuroretinal involvement by SARS-CoV2 might be linked to central neurological symptoms. The patients with lower GCLT values may benefit from close monitoring for neurological problems.

Indexed as

COVID-19CognitionHeadacheHumansRNA, ViralSARS-CoV-2Tomography, Optical CoherenceRNA, ViralBrain fogCOVID-19Ganglion cell layerHeadacheOptical coherence tomography

Identifiers

PMID35525105
PMCPMC9040445
OpenAlexW4224508108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.